These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 14709907)
1. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. Niwa T; Shiraga T; Hashimoto T; Kagayama A Biol Pharm Bull; 2004 Jan; 27(1):97-9. PubMed ID: 14709907 [TBL] [Abstract][Full Text] [Related]
2. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Niwa T; Shiraga T; Hashimoto T; Kagayama A Biol Pharm Bull; 2004 Mar; 27(3):415-7. PubMed ID: 14993813 [TBL] [Abstract][Full Text] [Related]
3. Effect of probucol on cytochrome P450 activities in human liver microsomes. Umehara K; Shimokawa Y; Miyamoto G Biol Pharm Bull; 2002 Aug; 25(8):1112-4. PubMed ID: 12186421 [TBL] [Abstract][Full Text] [Related]
4. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes. Umehara K; Shimokawa Y; Miyamoto G Biol Pharm Bull; 2004 Jul; 27(7):1151-3. PubMed ID: 15256760 [TBL] [Abstract][Full Text] [Related]
5. No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug. Niwa T; Inoue S; Shiraga T; Takagi A Biol Pharm Bull; 2005 Jan; 28(1):188-91. PubMed ID: 15635191 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Umehara K; Shimokawa Y; Miyamoto G Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517 [TBL] [Abstract][Full Text] [Related]
7. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes. Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538 [TBL] [Abstract][Full Text] [Related]
8. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes. Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922 [TBL] [Abstract][Full Text] [Related]
10. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Niwa T; Yamamoto S; Saito M; Shiraga T; Takagi A Yakugaku Zasshi; 2007 Jan; 127(1):209-16. PubMed ID: 17202802 [TBL] [Abstract][Full Text] [Related]
11. Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Niwa T; Yamamoto S; Saito M; Kobayashi N; Ikeda K; Noda Y; Takagi A Biol Pharm Bull; 2006 Sep; 29(9):1931-5. PubMed ID: 16946512 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063 [TBL] [Abstract][Full Text] [Related]
13. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064 [TBL] [Abstract][Full Text] [Related]
14. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906 [TBL] [Abstract][Full Text] [Related]
15. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150 [TBL] [Abstract][Full Text] [Related]
16. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Eagling VA; Tjia JF; Back DJ Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822 [TBL] [Abstract][Full Text] [Related]
17. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Easterbrook J; Fackett D; Li AP Chem Biol Interact; 2001 May; 134(3):243-9. PubMed ID: 11336973 [TBL] [Abstract][Full Text] [Related]
18. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Butler AM; Murray M J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313 [TBL] [Abstract][Full Text] [Related]
19. Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys. Nakanishi Y; Matsushita A; Matsuno K; Iwasaki K; Utoh M; Nakamura C; Uno Y Drug Metab Pharmacokinet; 2011 Jun; 26(3):288-94. PubMed ID: 21273732 [TBL] [Abstract][Full Text] [Related]
20. Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Yang J; He MM; Niu W; Wrighton SA; Li L; Liu Y; Li C Br J Clin Pharmacol; 2012 Feb; 73(2):268-84. PubMed ID: 21815912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]